Clinical Trials Logo

Cardiomyopathy, Secondary clinical trials

View clinical trials related to Cardiomyopathy, Secondary.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05445323 Recruiting - Friedreich Ataxia Clinical Trials

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

Start date: August 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy. The study will evaluate up to three doses of single administration of LX2006 (AAVrh.10hFXN), an adeno-associated virus (AAV) gene therapy designed to intravenously deliver the human frataxin (hFXN) gene to cardiac cells over a 52-week period. Long-term safety and efficacy will be evaluated for an additional 4-years for a total of 5-years post LX2006 treatment.